ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1457

Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry

Peter M. ten Klooster1,2, Laura M.M. Steunebrink3, Letty Versteeg4, Inmaculada de la Torre5, Francesco de Leonardis6, Walid Fakhouri6, Liliana Zaremba-Pechmann6 and Mart van de Laar1,3, 1Transparency in Healthcare B.V., Hengelo, Netherlands, 2Arthritis Centre Twente, University of Twente, Enschede, Netherlands, 3Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, 4Rheumatology, Arthritis Centre Twente, Medisch Spectrum Twente, Enschede, Netherlands, 5Eli Lilly and Company, Madrid, Spain, 6Eli Lilly and Company, Indianapolis, IN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Disease Activity, Early Rheumatoid Arthritis, radiography, registry and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Recent studies suggested a disconnect between disease activity and radiographic damage in rheumatoid arthritis (RA) patients treated with more aggressive treatment (1). Therefore, the aim of this retrospective study was to examine the longitudinal association between disease activity and radiographic damage in a real world cohort of consecutive patients with early RA treated according to treat-to-target (T2T) of remission step-up therapy.

Methods: Baseline to 3-year follow-up data were used from patients with early RA (79% fulfilling ACR 1987 criteria) included in the DREAM remission induction cohort (2). Patients were treated according to protocolized T2T, aimed at 28-joint disease activity score-erythrocyte sedimentation rate (DAS28-ESR) <2.6. Disease activity assessments were performed every 3 months; X-rays of the hand and feet were assessed at baseline and after 0.5, 1, 2 and 3 years of treatment and scored using modified Sharp/van der Heijde scoring (SHS). Between and within-person relations between time-integrated disease activity scores (DAS28-ESR and CRP) and radiographic change scores over time were examined using Pearson correlations.

Results: 229 patients (63.3% female, mean age 57.5 years, baseline median symptom duration 13 weeks) with at least two radiographic assessments in the first 3 years were available for analysis. At the between-patient level, time-integrated DAS28-ESR scores were not significantly correlated with progression at the 6 month (r=0.06) and 2-year follow-up (r=0.11) and only weakly at the 1-year (r=0.17, P<0.05) and 3-year follow-up (r=0.21, P<0.05). Within individual patients, however, a different but fairly linear relationship between disease activity and progression existed over time (Figure). Individual slopes of the relationship between disease activity and progression were significantly correlated at each time point (Table) and the slope of the first 6 months was moderately significantly associated with this slope at later time points. Analyses using CRP showed similar results.

 

 

6 months

1 year

2 year

3 year

6 months

–

 

 

 

1 year

0.394***

–

 

 

2 year

0.527***

0.172*

–

 

3 year

0.592***

0.252**

0.478***

–

* P<0.05; ** P<0.01; *** P<0.001.

Conclusion: In early RA patients treated according to T2T, radiographic progression appears to be an individually determined disease process, driven by factors other than consistent high disease activity. Within individual patients, the association between disease activity and radiographic damage during the first 6 months in individuals seems to be a good indicator for the progression and its association with disease activity in later years.

References

1. Ann Rheum Dis. 2013;72(2):307–8.

2. Arthritis Rheum. 2011;63(10):2865–72.


Disclosure: P. M. ten Klooster, None; L. M. M. Steunebrink, None; L. Versteeg, None; I. de la Torre, Eli Lilly and Company, 1, 3; F. de Leonardis, Eli Lilly and Company, 1, 3; W. Fakhouri, Eli Lilly and Company, 1, 3; L. Zaremba-Pechmann, Eli Lilly and Company, 9; M. van de Laar, None.

To cite this abstract in AMA style:

ten Klooster PM, Steunebrink LMM, Versteeg L, de la Torre I, de Leonardis F, Fakhouri W, Zaremba-Pechmann L, van de Laar M. Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/association-between-disease-activity-and-radiographic-progression-in-the-current-treat-to-target-paradigm-of-rheumatoid-arthritis-real-world-data-from-the-dutch-rheumatoid-arthritis-monitoring-dream/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-disease-activity-and-radiographic-progression-in-the-current-treat-to-target-paradigm-of-rheumatoid-arthritis-real-world-data-from-the-dutch-rheumatoid-arthritis-monitoring-dream/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology